Active Ingredient History

NOW
  • Now
Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.   Wikipedia

More Chemistry

Drug Pricing (per unit)

Australia

$2051.9981
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

abbv-066 | bi 655066 | risankizumab

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue